WWWW International, Inc.
The schedule
- Thu15Oct
An expected intra-quarter strategic update as the fall diet season begins, evaluating WW's competitive positioning against direct-to-consumer telehealth platforms. Upside to $11.50 requires proof of CAC (Customer Acquisition Cost) efficiency, while a failure to defend market share points to $7.00.
- Fri15Jan
Anticipated timeline for a mandatory liquidity event. Securing financing or modifying covenants could provide a strategic de-risking relief rally to $6.50, whereas toxic financing terms would drag the equity floor down to $3.50.
- Mon8Feb
Q3 2026 results will be a critical liquidity check. With a starting $126M cash balance in Q1 and severe ongoing FCF drains, a strong print could lift shares to $8.50, but an unresolved cash crunch risks a collapse to $5.00.
- Thu15Apr
Expected policy guidance from President Trump's Centers for Medicare & Medicaid Services regarding potential coverage expansions for Anti-Obesity Medications (AOMs). Positive coverage mandates could boost WW to $6.00; exclusion keeps the stock anchored at $3.50.
- Mon10May
WW's FY27 forward guidance will reveal the ultimate stabilization rate of its core business. A credible pivot back to growth targets $8.50, while continued margin deterioration points to a $4.50 baseline.
- Mon9Aug
Past
- Mon10Aug
Actual outcome: Bear · $13.58 at outcome
WW reported Q2 2026 revenue of $162.3 million, a significant decline from $189.2 million a year earlier, while meeting EPS estimates of -$5.20. Although the company highlighted strong growth in its Clinical subscribers (up 55.7% YoY) and reaffirmed its full-year outlook, the broader revenue contraction overshadowed these bright spots, driving a 14.4% decline in the stock price.
WW will report Q2 2026 earnings, focusing on the offsetting of the 9.8% YoY revenue decline with WW Clinic (GLP-1) subscriber growth. The market expects a favorable target of $15.50 if clinical momentum accelerates, or a fallback of $9.50 if the -$39M FCF burn rate fails to stabilize.